Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1993 Jun;68(6):719–721. doi: 10.1136/adc.68.6.719

Corticosteroid treatment in cystic fibrosis.

J F Price 1, P Greally 1
PMCID: PMC1029359  PMID: 8333757

Full text

PDF
719

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Auerbach H. S., Williams M., Kirkpatrick J. A., Colten H. R. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis. Lancet. 1985 Sep 28;2(8457):686–688. doi: 10.1016/s0140-6736(85)92929-0. [DOI] [PubMed] [Google Scholar]
  2. Baggiolini M., Walz A., Kunkel S. L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J Clin Invest. 1989 Oct;84(4):1045–1049. doi: 10.1172/JCI114265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bauldry S. A., McCall C. E., Cousart S. L., Bass D. A. Tumor necrosis factor-alpha priming of phospholipase A2 activation in human neutrophils. An alternative mechanism of priming. J Immunol. 1991 Feb 15;146(4):1277–1285. [PubMed] [Google Scholar]
  4. Bedrossian C. W., Greenberg S. D., Singer D. B., Hansen J. J., Rosenberg H. S. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum Pathol. 1976 Mar;7(2):195–204. doi: 10.1016/s0046-8177(76)80023-8. [DOI] [PubMed] [Google Scholar]
  5. Blackwell G. J., Carnuccio R., Di Rosa M., Flower R. J., Parente L., Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980 Sep 11;287(5778):147–149. doi: 10.1038/287147a0. [DOI] [PubMed] [Google Scholar]
  6. Bruce M. C., Poncz L., Klinger J. D., Stern R. C., Tomashefski J. F., Jr, Dearborn D. G. Biochemical and pathologic evidence for proteolytic destruction of lung connective tissue in cystic fibrosis. Am Rev Respir Dis. 1985 Sep;132(3):529–535. doi: 10.1164/arrd.1985.132.3.529. [DOI] [PubMed] [Google Scholar]
  7. Carlstedt-Duke J., Brönnegård M., Strandvik B. Pathological regulation of arachidonic acid release in cystic fibrosis: the putative basic defect. Proc Natl Acad Sci U S A. 1986 Dec;83(23):9202–9206. doi: 10.1073/pnas.83.23.9202. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dagli E., Warner J. A., Besley C. R., Warner J. O. Raised serum soluble interleukin-2 receptor concentrations in cystic fibrosis patients with and without evidence of lung disease. Arch Dis Child. 1992 Apr;67(4):479–481. doi: 10.1136/adc.67.4.479. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dinarello C. A. Interleukin-1. Rev Infect Dis. 1984 Jan-Feb;6(1):51–95. doi: 10.1093/clinids/6.1.51. [DOI] [PubMed] [Google Scholar]
  10. Fick R. B., Jr, Robbins R. A., Squier S. U., Schoderbek W. E., Russ W. D. Complement activation in cystic fibrosis respiratory fluids: in vivo and in vitro generation of C5a and chemotactic activity. Pediatr Res. 1986 Dec;20(12):1258–1268. doi: 10.1203/00006450-198612000-00014. [DOI] [PubMed] [Google Scholar]
  11. Gillis S., Crabtree G. R., Smith K. A. Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol. 1979 Oct;123(4):1624–1631. [PubMed] [Google Scholar]
  12. Greally P., Hussein M. J., Cook A. J., Sampson A. P., Piper P. J., Price J. F. Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child. 1993 Mar;68(3):389–392. doi: 10.1136/adc.68.3.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Hong S. L., Levine L. Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticosteroids. Proc Natl Acad Sci U S A. 1976 May;73(5):1730–1734. doi: 10.1073/pnas.73.5.1730. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Horst H. J., Flad H. D. Corticosteroid-interleukin 2 interactions: inhibition of binding of interleukin 2 to interleukin 2 receptors. Clin Exp Immunol. 1987 Apr;68(1):156–161. [PMC free article] [PubMed] [Google Scholar]
  15. Kharazmi A. Interactions of Pseudomonas aeruginosa proteases with the cells of the immune system. Antibiot Chemother (1971) 1989;42:42–49. doi: 10.1159/000417602. [DOI] [PubMed] [Google Scholar]
  16. Klebanoff S. J., Vadas M. A., Harlan J. M., Sparks L. H., Gamble J. R., Agosti J. M., Waltersdorph A. M. Stimulation of neutrophils by tumor necrosis factor. J Immunol. 1986 Jun 1;136(11):4220–4225. [PubMed] [Google Scholar]
  17. Lemen R. J., Gates A. J., Mathé A. A., Waring W. W., Hyman A. L., Kadowitz P. D. Relationships among digital clubbing, disease severity, and serum prostaglandins F2alpha and E concentrations in cystic fibrosis patients. Am Rev Respir Dis. 1978 Apr;117(4):639–646. doi: 10.1164/arrd.1978.117.4.639. [DOI] [PubMed] [Google Scholar]
  18. Meyer K. C., Lewandoski J. R., Zimmerman J. J., Nunley D., Calhoun W. J., Dopico G. A. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Am Rev Respir Dis. 1991 Sep;144(3 Pt 1):580–585. doi: 10.1164/ajrccm/144.3_Pt_1.580. [DOI] [PubMed] [Google Scholar]
  19. Ming W. J., Bersani L., Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 1987 Mar 1;138(5):1469–1474. [PubMed] [Google Scholar]
  20. Moss R. B., Hsu Y. P., Sullivan M. M., Lewiston N. J. Altered antibody isotype in cystic fibrosis: possible role in opsonic deficiency. Pediatr Res. 1986 May;20(5):453–459. doi: 10.1203/00006450-198605000-00015. [DOI] [PubMed] [Google Scholar]
  21. Neuber K., Hilger R. A., König W. Interleukin-3, interleukin-8, FMLP and C5a enhance the release of leukotrienes from neutrophils of patients with atopic dermatitis. Immunology. 1991 May;73(1):83–87. [PMC free article] [PubMed] [Google Scholar]
  22. Pantin C. F., Stead R. J., Hodson M. E., Batten J. C. Prednisolone in the treatment of airflow obstruction in adults with cystic fibrosis. Thorax. 1986 Jan;41(1):34–38. doi: 10.1136/thx.41.1.34. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pohlman T. H., Stanness K. A., Beatty P. G., Ochs H. D., Harlan J. M. An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin 1, and tumor necrosis factor-alpha increases neutrophil adherence by a CDw18-dependent mechanism. J Immunol. 1986 Jun 15;136(12):4548–4553. [PubMed] [Google Scholar]
  24. Rosenstein B. J., Eigen H. Risks of alternate-day prednisone in patients with cystic fibrosis. Pediatrics. 1991 Feb;87(2):245–246. [PubMed] [Google Scholar]
  25. Roubin R., Elsas P. P., Fiers W., Dessein A. J. Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187. Clin Exp Immunol. 1987 Nov;70(2):484–490. [PMC free article] [PubMed] [Google Scholar]
  26. Safirstein B. H., D'Souza M. F., Simon G., Tai E. H., Pepys J. Five-year follow-up of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis. 1973 Sep;108(3):450–459. doi: 10.1164/arrd.1973.108.3.450. [DOI] [PubMed] [Google Scholar]
  27. Sampson A. P., Spencer D. A., Green C. P., Piper P. J., Price J. F. Leukotrienes in the sputum and urine of cystic fibrosis children. Br J Clin Pharmacol. 1990 Dec;30(6):861–869. doi: 10.1111/j.1365-2125.1990.tb05452.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schiøtz P. O., Jørgensen M., Flensborg E. W., Faerø O., Husby S., Høiby N., Jacobsen S. V., Nielsen H., Svehag S. E. Chronic Pseudomonas aeruginosa lung infection in cystic fibrosis. A longitudinal study of immune complex activity and inflammatory response in sputum sol-phase of cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infections: influence of local steroid treatment. Acta Paediatr Scand. 1983 Mar;72(2):283–287. doi: 10.1111/j.1651-2227.1983.tb09712.x. [DOI] [PubMed] [Google Scholar]
  29. Schiøtz P. O., Nielsen H., Høiby N., Glikmann G., Svehag S. E. Immune complexes in the sputum of patients with cystic fibrosis suffering from chronic Pseudomonas aeruginosa lung infection. Acta Pathol Microbiol Scand C. 1978 Feb;86(1):37–40. doi: 10.1111/j.1699-0463.1978.tb02555.x. [DOI] [PubMed] [Google Scholar]
  30. Schleimer R. P. Effects of glucocorticosteroids on inflammatory cells relevant to their therapeutic applications in asthma. Am Rev Respir Dis. 1990 Feb;141(2 Pt 2):S59–S69. [PubMed] [Google Scholar]
  31. Sebaldt R. J., Sheller J. R., Oates J. A., Roberts L. J., 2nd, FitzGerald G. A. Inhibition of eicosanoid biosynthesis by glucocorticoids in humans. Proc Natl Acad Sci U S A. 1990 Sep;87(18):6974–6978. doi: 10.1073/pnas.87.18.6974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Seggev J. S., Thornton W. H., Jr, Edes T. E. Serum leukotriene B4 levels in patients with obstructive pulmonary disease. Chest. 1991 Feb;99(2):289–291. doi: 10.1378/chest.99.2.289. [DOI] [PubMed] [Google Scholar]
  33. Stead R. J., Barradas M. A., Mikhailidis D. P., Jeremy J. Y., Hodson M. E., Batten J. C., Dandona P. Platelet hyperaggregability in cystic fibrosis. Prostaglandins Leukot Med. 1987 Feb;26(2):91–103. doi: 10.1016/0262-1746(87)90104-1. [DOI] [PubMed] [Google Scholar]
  34. Strieter R. M., Chensue S. W., Basha M. A., Standiford T. J., Lynch J. P., Baggiolini M., Kunkel S. L. Human alveolar macrophage gene expression of interleukin-8 by tumor necrosis factor-alpha, lipopolysaccharide, and interleukin-1 beta. Am J Respir Cell Mol Biol. 1990 Apr;2(4):321–326. doi: 10.1165/ajrcmb/2.4.321. [DOI] [PubMed] [Google Scholar]
  35. Suter S., Schaad U. B., Roux-Lombard P., Girardin E., Grau G., Dayer J. M. Relation between tumor necrosis factor-alpha and granulocyte elastase-alpha 1-proteinase inhibitor complexes in the plasma of patients with cystic fibrosis. Am Rev Respir Dis. 1989 Dec;140(6):1640–1644. doi: 10.1164/ajrccm/140.6.1640. [DOI] [PubMed] [Google Scholar]
  36. Wheeler W. B., Williams M., Matthews W. J., Jr, Colten H. R. Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study. J Pediatr. 1984 May;104(5):695–699. doi: 10.1016/s0022-3476(84)80946-4. [DOI] [PubMed] [Google Scholar]
  37. Wilmott R. W., Kassab J. T., Kilian P. L., Benjamin W. R., Douglas S. D., Wood R. E. Increased levels of interleukin-1 in bronchoalveolar washings from children with bacterial pulmonary infections. Am Rev Respir Dis. 1990 Aug;142(2):365–368. doi: 10.1164/ajrccm/142.2.365. [DOI] [PubMed] [Google Scholar]
  38. Wisnieski J. J., Todd E. W., Fuller R. K., Jones P. K., Dearborn D. G., Boat T. F., Naff G. B. Immune complexes and complement abnormalities in patients with cystic fibrosis. Increased mortality associated with circulating immune complexes and decreased function of the alternative complement pathway. Am Rev Respir Dis. 1985 Oct;132(4):770–776. doi: 10.1164/arrd.1985.132.4.770. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES